Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
NCT04024761Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2019
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN) and 1 more, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Safety at 6 weeks. Started Aug 2019; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT04024761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024761.